$LENZ
LENZ Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023021242 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.455M $7.623M $7.712M
YoY Change -17.16% -1.15% 93.23%
% of Gross Profit
Research & Development $13.51M $16.24M $18.25M
YoY Change -24.01% -10.97% 239.33%
% of Gross Profit
Depreciation & Amortization $800.0K $700.0K $400.0K
YoY Change 33.33% 75.0% 300.0%
% of Gross Profit
Operating Expenses $58.16M $26.45M $25.96M
YoY Change 117.21% 1.9% 177.09%
Operating Profit -$58.16M -$26.45M -$25.96M
YoY Change 117.21% 1.9% 177.09%
Interest Expense $2.850M $2.590M
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.845M $2.516M $123.0K
YoY Change 238.69% 1945.53% -101.19%
Pretax Income -$55.31M -$23.93M -$25.84M
YoY Change 113.27% -7.36% 31.08%
Income Tax
% Of Pretax Income
Net Earnings -$55.31M -$23.93M -$25.84M
YoY Change 113.27% -7.36% 31.08%
Net Earnings / Revenue
Basic Earnings Per Share -$0.97 -$0.43 -$0.48
Diluted Earnings Per Share -$0.97 -$0.43 -$478.4K
COMMON SHARES
Basic Shares Outstanding 58.10M 58.16M 58.01M
Diluted Shares Outstanding 56.75M 55.86M 54.01M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $246.7M $264.1M $339.2M
YoY Change -23.47% -22.14% 91.61%
Cash & Equivalents $128.5M $69.81M $185.1M
Short-Term Investments $118.2M $194.3M $154.1M
Other Short-Term Assets $4.506M $6.211M $4.574M
YoY Change 3.54% 35.79% 40.7%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $251.2M $270.3M $343.8M
YoY Change -23.11% -21.37% 90.69%
LONG-TERM ASSETS
Property, Plant & Equipment $17.97M $33.07M $9.374M
YoY Change 71.63% 252.78% 388.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $12.93M
YoY Change -100.0% -100.0%
Other Assets $355.0K $889.0K $711.0K
YoY Change 5.97% 25.04% -2.34%
Total Long-Term Assets $35.87M $39.69M $34.85M
YoY Change 32.17% 13.89% 1217.08%
TOTAL ASSETS
Total Short-Term Assets $251.2M $270.3M $343.8M
Total Long-Term Assets $35.87M $39.69M $34.85M
Total Assets $287.0M $310.0M $378.6M
YoY Change -18.87% -18.12% 106.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.720M $1.992M $3.069M
YoY Change -24.84% -35.09% 91.1%
Accrued Expenses $9.550M $12.35M $500.0K
YoY Change 13.03% 2369.8% -89.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.27M $14.34M $12.77M
YoY Change 1.67% 12.35% 99.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $50.63M $19.43M $4.542M
YoY Change 1452.05% 327.81% 6996.88%
Total Long-Term Liabilities $50.63M $19.43M $4.542M
YoY Change 1452.05% 327.81% 6996.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.27M $14.34M $12.77M
Total Long-Term Liabilities $50.63M $19.43M $4.542M
Total Liabilities $62.90M $33.77M $17.31M
YoY Change 310.29% 95.13% 168.03%
SHAREHOLDERS EQUITY
Retained Earnings -$321.7M -$266.3M -$167.2M
YoY Change 66.6% 59.27%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $224.1M $276.2M $361.3M
YoY Change
Total Liabilities & Shareholders Equity $287.0M $310.0M $378.6M
YoY Change -18.87% -18.12% 106.99%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$55.31M -$23.93M -$25.84M
YoY Change 113.27% -7.36% 31.08%
Depreciation, Depletion And Amortization $800.0K $700.0K $400.0K
YoY Change 33.33% 75.0% 300.0%
Cash From Operating Activities -$13.65M -$21.07M -$21.24M
YoY Change -38.2% -0.78% 163.52%
INVESTING ACTIVITIES
Capital Expenditures $5.610M $383.0K $3.273M
YoY Change -505.05% -88.3% 809.17%
Acquisitions
YoY Change
Other Investing Activities $77.84M $43.55M -$167.4M
YoY Change -189.64% -126.01%
Cash From Investing Activities $72.23M $43.16M -$170.7M
YoY Change -181.87% -125.29% 47307.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 124.0K -8.000K 0.000
YoY Change -69.9% -100.0%
NET CHANGE
Cash From Operating Activities -13.65M -21.07M -21.24M
Cash From Investing Activities 72.23M 43.16M -170.7M
Cash From Financing Activities 124.0K -8.000K 0.000
Net Change In Cash 58.70M 22.08M -191.9M
YoY Change -153.41% -111.51% -221.96%
FREE CASH FLOW
Cash From Operating Activities -$13.65M -$21.07M -$21.24M
Capital Expenditures $5.610M $383.0K $3.273M
Free Cash Flow -$19.26M -$21.46M -$24.51M
YoY Change -6.97% -12.47% 191.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001815776
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-40532
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
GRAPHITE BIO, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4867570
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
201 Haskins Way
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 210
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2023Q1 dei City Area Code
CityAreaCode
650
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
484-0886
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
GRPH
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58102949
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69811000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47730000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
194285000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
220499000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6211000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7136000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
270307000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
275365000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1716000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1716000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
15322000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33070000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22630000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4014000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5580000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
889000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1289000
CY2023Q1 us-gaap Assets
Assets
309996000
CY2022Q4 us-gaap Assets
Assets
321902000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1992000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2608000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1314000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3799000
CY2023Q1 grph Accrued Research Costs
AccruedResearchCosts
596000
CY2022Q4 grph Accrued Research Costs
AccruedResearchCosts
720000
CY2023Q1 grph Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7317000
CY2022Q4 grph Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1871000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3122000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4045000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
14341000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13043000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1419000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1749000
CY2023Q1 us-gaap Other Liabilities
OtherLiabilities
18012000
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
10819000
CY2023Q1 us-gaap Liabilities
Liabilities
33772000
CY2022Q4 us-gaap Liabilities
Liabilities
25611000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58194818
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58194818
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58221760
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58221760
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
543029000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
539741000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-469000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1048000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-266337000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242403000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
276224000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
296291000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
309996000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
321902000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16244000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18246000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7623000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7712000
CY2023Q1 us-gaap Restructuring Costs
RestructuringCosts
2583000
CY2022Q1 us-gaap Restructuring Costs
RestructuringCosts
0
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
26450000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
25958000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26450000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-25958000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2587000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
123000
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-71000
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2516000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
123000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-23934000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25835000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
579000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-309000
CY2023Q1 grph Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-23355000
CY2022Q1 grph Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-26144000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55864475
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55864475
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54005299
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54005299
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
296291000
CY2023Q1 grph Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
25000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3263000
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
579000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-23934000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
276224000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
384050000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3342000
CY2022Q1 grph Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
51000
CY2022Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-309000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25835000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
361299000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-23934000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-25835000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1562000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-45000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
654000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
440000
CY2023Q1 grph Non Cash Lease Expense
NonCashLeaseExpense
1566000
CY2022Q1 grph Non Cash Lease Expense
NonCashLeaseExpense
1452000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3263000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3342000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1457000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
71000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-591000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
582000
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2485000
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1666000
CY2023Q1 grph Increase Decrease In Accrued Research Costs
IncreaseDecreaseInAccruedResearchCosts
-124000
CY2022Q1 grph Increase Decrease In Accrued Research Costs
IncreaseDecreaseInAccruedResearchCosts
1246000
CY2023Q1 grph Increase Decrease In Accrued Expenses And Other Current Liabilities And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilitiesAndOtherLiabilities
1935000
CY2022Q1 grph Increase Decrease In Accrued Expenses And Other Current Liabilities And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilitiesAndOtherLiabilities
323000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1253000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1098000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21074000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21240000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
383000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3273000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
28129000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
167393000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
71675000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43163000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-170666000
CY2023Q1 grph Repurchase Of Unvested Early Exercised Shares
RepurchaseOfUnvestedEarlyExercisedShares
8000
CY2022Q1 grph Repurchase Of Unvested Early Exercised Shares
RepurchaseOfUnvestedEarlyExercisedShares
0
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22081000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-191906000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49446000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
378692000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71527000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
186786000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69811000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
185070000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
1716000
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
1716000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71527000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
186786000
CY2023Q1 grph Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
-4655000
CY2022Q1 grph Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
-109000
CY2023Q1 grph Lessor Funded Lease Incentive Additions Included In Property And Equipment
LessorFundedLeaseIncentiveAdditionsIncludedInPropertyAndEquipment
7193000
CY2022Q1 grph Lessor Funded Lease Incentive Additions Included In Property And Equipment
LessorFundedLeaseIncentiveAdditionsIncludedInPropertyAndEquipment
0
CY2023Q1 grph Noncash Or Part Noncash Vesting Of Early Exercised Stock Options
NoncashOrPartNoncashVestingOfEarlyExercisedStockOptions
25000
CY2022Q1 grph Noncash Or Part Noncash Vesting Of Early Exercised Stock Options
NoncashOrPartNoncashVestingOfEarlyExercisedStockOptions
51000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-266300000
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
264.1
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.173%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the marketable securities, stock-based compensation expense, accruals for research and development costs, lease assets and liabilities, the valuation of deferred tax assets, and uncertain income tax positions. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span></p>
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
1700000
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
194754000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
476000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
194285000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
236869000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
28000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1076000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
235821000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
194300000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
0
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q1 us-gaap Supplies
Supplies
2063000
CY2022Q4 us-gaap Supplies
Supplies
2486000
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
668000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1343000
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3480000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3307000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6211000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7136000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36932000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25837000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3862000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3207000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33070000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22630000
CY2023Q1 us-gaap Depreciation
Depreciation
700000
CY2022Q1 us-gaap Depreciation
Depreciation
400000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
157000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
367000
CY2023Q1 grph Accrued Early Exercise Liability
AccruedEarlyExerciseLiability
118000
CY2022Q4 grph Accrued Early Exercise Liability
AccruedEarlyExerciseLiability
150000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4889000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1354000
CY2023Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2153
CY2023Q1 grph Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7317000
CY2022Q4 grph Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1871000
CY2023Q1 grph Royalty Payment Due
RoyaltyPaymentDue
0
CY2022 grph Royalty Payment Due
RoyaltyPaymentDue
0
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3100000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1400000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P17M
CY2023Q1 grph Lessee Operating Lease Weighted Average Incremental Borrowing Rate
LesseeOperatingLeaseWeightedAverageIncrementalBorrowingRate
0.086
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2974000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1468000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
375000
CY2023Q1 grph Lesseeoperatingleaseliabilitypaymentsdueaftertwoyear
Lesseeoperatingleaseliabilitypaymentsdueaftertwoyear
0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4817000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
276000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
4541000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
400000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
300000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1745000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17395191
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13893161
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
The shares of the Company’s common stock issued to its founders for their services as an employee, advisor, or consultant vest monthly over four years with one year cliff from the vesting commencement date.
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2023Q1 grph Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod
P1Y
CY2020Q2 grph Aggregate Common Stock Vested
AggregateCommonStockVested
912212
CY2020Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
7273848
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.53
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2023Q1 grph Early Exercise Of Stock Options Repurchase Right Lapse Period
EarlyExerciseOfStockOptionsRepurchaseRightLapsePeriod
P180D
CY2023Q1 grph Stock Issued During Period Shares Stock Options Exercised And Repurchased
StockIssuedDuringPeriodSharesStockOptionsExercisedAndRepurchased
26942
CY2022Q1 grph Stock Issued During Period Shares Stock Options Exercised And Repurchased
StockIssuedDuringPeriodSharesStockOptionsExercisedAndRepurchased
0
CY2023Q1 grph Share Based Compensation Arrangement By Share Based Payment Award Remained Subject To Right Of Repurchase Of Early Exercised Stock Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainedSubjectToRightOfRepurchaseOfEarlyExercisedStockOptions
391928
CY2022Q4 grph Share Based Compensation Arrangement By Share Based Payment Award Remained Subject To Right Of Repurchase Of Early Exercised Stock Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainedSubjectToRightOfRepurchaseOfEarlyExercisedStockOptions
554695
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3263000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3342000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3263000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3342000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
0
CY2023Q1 grph Severance Costs Incurred
SeveranceCostsIncurred
2545000
CY2023Q1 us-gaap Severance Costs1
SeveranceCosts1
-430000
CY2023Q1 grph Accrued Employee Termination Benefits Ending Balance
AccruedEmployeeTerminationBenefitsEndingBalance
2115000
CY2023Q1 grph Employees Retention Bonus Payable
EmployeesRetentionBonusPayable
4000000.0
CY2023Q1 grph Employees Retention Bonus Amount
EmployeesRetentionBonusAmount
300000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-23934000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25835000
CY2023Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
58208588
CY2022Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
58010823
CY2023Q1 grph Weighted Average Unvested Restricted Shares And Shares Subject To Repurchase Or Cancellation
WeightedAverageUnvestedRestrictedSharesAndSharesSubjectToRepurchaseOrCancellation
-2344113
CY2022Q1 grph Weighted Average Unvested Restricted Shares And Shares Subject To Repurchase Or Cancellation
WeightedAverageUnvestedRestrictedSharesAndSharesSubjectToRepurchaseOrCancellation
-4005524
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55864475
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55864475
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54005299
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54005299
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12227079
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11388123

Files In Submission

Name View Source Status
grph-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0000950170-23-021242-index-headers.html Edgar Link pending
0000950170-23-021242-index.html Edgar Link pending
0000950170-23-021242.txt Edgar Link pending
0000950170-23-021242-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
grph-20230331.htm Edgar Link pending
grph-20230331.xsd Edgar Link pending
grph-ex31_1.htm Edgar Link pending
grph-ex31_2.htm Edgar Link pending
grph-ex32_1.htm Edgar Link pending
grph-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
grph-20230331_cal.xml Edgar Link unprocessable
grph-20230331_lab.xml Edgar Link unprocessable
grph-20230331_pre.xml Edgar Link unprocessable
grph-20230331_htm.xml Edgar Link completed
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending